Paulsen is the owner and chairman of Ferring, a drugmaker that specializes in medicines for reproductive medicine and women's health. The Saint-Prex, Switzerland-based company's products include fertility treatments Menopur and Rekovelle. Ferring had revenue of 2.2 billion euros ($2.6 billion) in 2021.
Frederik Paulsen's net worth of $6.52B can buy ...
... and is equivalent to ...
Paulsen is the majority owner of Ferring Pharmaceuticals, the drugmaker founded by his father in 1950.
The closely held business is valued using the average enterprise value-to-sales multiple of three publicly traded peer companies: H Lundbeck, Ipsen and Endo.
Paulsen is also the majority owner of Swiss biotechnology company PolyPeptide, which makes ingredients for vaccines. He controls a 55% stake in the firm via holding company Draupnir Holding, according to company's 2021 annual report.
Paulsen didn't respond to e-mail and telephone messages requesting comment on his net worth.
Frederik Paulsen was born in 1950 in Malmo, Sweden, the same year his father founded Nordiska Hormon Laboratoriet. The company was renamed Ferring four years later. Paulsen studied chemistry at the Christian-Albrechts-University in Kiel, Germany, and business administration at the University of Lund in Sweden.
He started work at Ferring in 1976, heading its Swedish division seven years later, and becoming chief executive officer of the group in 1988. He transferred Ferring's headquarters to Saint-Prex from Malmo in 2006 and today is the company's chairman.
The billionaire also is an explorer and spends much of his time planning and participating in scientific trips, including a trip to the Arctic seabed in 2007. He is married and has three children.